257 related articles for article (PubMed ID: 15131025)
1. BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
Kirchhoff T; Kauff ND; Mitra N; Nafa K; Huang H; Palmer C; Gulati T; Wadsworth E; Donat S; Robson ME; Ellis NA; Offit K
Clin Cancer Res; 2004 May; 10(9):2918-21. PubMed ID: 15131025
[TBL] [Abstract][Full Text] [Related]
2. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
4. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
[TBL] [Abstract][Full Text] [Related]
5. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
[TBL] [Abstract][Full Text] [Related]
6. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K
J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740
[TBL] [Abstract][Full Text] [Related]
7. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
Agalliu I; Gern R; Leanza S; Burk RD
Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187
[TBL] [Abstract][Full Text] [Related]
8. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
9. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
10. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB
J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734
[TBL] [Abstract][Full Text] [Related]
12. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
13. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
14. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
15. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
16. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Im KM; Kirchhoff T; Wang X; Green T; Chow CY; Vijai J; Korn J; Gaudet MM; Fredericksen Z; Shane Pankratz V; Guiducci C; Crenshaw A; McGuffog L; Kartsonaki C; Morrison J; Healey S; Sinilnikova OM; Mai PL; Greene MH; Piedmonte M; Rubinstein WS; ; Hogervorst FB; Rookus MA; Collée JM; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer HE; Van Roozendaal CE; Caldes T; Perez-Segura P; Jakubowska A; Lubinski J; Huzarski T; Blecharz P; Nevanlinna H; Aittomäki K; Lazaro C; Blanco I; Barkardottir RB; Montagna M; D'Andrea E; ; Devilee P; Olopade OI; Neuhausen SL; Peissel B; Bonanni B; Peterlongo P; Singer CF; Rennert G; Lejbkowicz F; Andrulis IL; Glendon G; Ozcelik H; ; Toland AE; Caligo MA; ; Beattie MS; Chan S; ; Domchek SM; Nathanson KL; Rebbeck TR; Phelan C; Narod S; John EM; Hopper JL; Buys SS; Daly MB; Southey MC; Terry MB; Tung N; Hansen TV; Osorio A; Benitez J; Durán M; Weitzel JN; Garber J; Hamann U; ; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Eeles R; Izatt L; Paterson J; Brewer C; Hodgson S; Morrison PJ; Porteous M; Walker L; Rogers MT; Side LE; Godwin AK; Schmutzler RK; Wappenschmidt B; Laitman Y; Meindl A; Deissler H; Varon-Mateeva R; Preisler-Adams S; Kast K; Venat-Bouvet L; Stoppa-Lyonnet D; Chenevix-Trench G; Easton DF; Klein RJ; Daly MJ; Friedman E; Dean M; Clark AG; Altshuler DM; Antoniou AC; Couch FJ; Offit K; Gold B
Hum Genet; 2011 Nov; 130(5):685-99. PubMed ID: 21597964
[TBL] [Abstract][Full Text] [Related]
17. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME; Chappuis PO; Satagopan J; Wong N; Boyd J; Goffin JR; Hudis C; Roberge D; Norton L; Bégin LR; Offit K; Foulkes WD
Breast Cancer Res; 2004; 6(1):R8-R17. PubMed ID: 14680495
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Holter S; Borgida A; Dodd A; Grant R; Semotiuk K; Hedley D; Dhani N; Narod S; Akbari M; Moore M; Gallinger S
J Clin Oncol; 2015 Oct; 33(28):3124-9. PubMed ID: 25940717
[TBL] [Abstract][Full Text] [Related]
19. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
20. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men.
Nastiuk KL; Mansukhani M; Terry MB; Kularatne P; Rubin MA; Melamed J; Gammon MD; Ittmann M; Krolewski JJ
Prostate; 1999 Aug; 40(3):172-7. PubMed ID: 10398279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
